Preliminary tolerability and anti-tumor activity of intravenous recombinant human Interleukin-21 (IL-21) in patients with metastatic melanoma and metastatic renal cell carcinoma.

被引：0
|
作者：
Curti, BD
Redman, BG
Thompson, JA
Sievers, EL
机构：
[1] Providence Portland Med Ctr, Portland, OR USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Zymogenet Inc, Seattle, WA 98105 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：166S / 166S
页数：1
相关论文
共 50 条
  • [1] Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma (MM)
    Petrella, T. M.
    Tozer, R.
    Belanger, K.
    Savage, K. J.
    Wong, R.
    Kamel-Reid, S.
    Tron, V.
    Chen, B.
    Hunder, N. N.
    Eisenhauer, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Phase 1 dose-escalation study of intravenous recombinant human Interleukin-21 (IL-21) in patients with metastatic melanoma: preliminary results of tolerability and effect on immunologic biomarkers
    McArthur, G. A.
    Cebon, J.
    Skrumsager, B. K.
    Skak, K.
    Davis, I. D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 148 - 148
  • [3] Interleukin-21 (IL-21): Tolerability and anti-tumor activity following two 5-day cycles in patients with stage IV melanoma (MM) or renal cell carcinoma (RCC).
    Thompson, J. A.
    Curti, B. D.
    Redman, B. G.
    Weber, J. S.
    Agarwala, S. S.
    Sievers, E. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 101S - 101S
  • [4] Identification of a well-tolerated outpatient regimen of interleukin-21 (IL-21) in patients with metastatic melanoma and renal cell carcinoma (RCC)
    Thompson, JA
    Curti, BD
    Redman, BG
    Sievers, EL
    JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) : 641 - 642
  • [5] Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma
    Thompson, John A.
    Curti, Brendan D.
    Redman, Bruce G.
    Bhatia, Shailender
    Weber, Jeffrey S.
    Agarwala, Sanjiv S.
    Sievers, Eric L.
    Hughes, Steven D.
    DeVries, Todd A.
    Hausman, Diana F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 2034 - 2039
  • [6] Recombinant human Interleukin-21 (IL-21) is well tolerated and can mediate biological effects in patients with metastatic melanoma (MM): preliminary results of a phase 1 study
    Davis, Ian D.
    McArthur, Grant
    Cebon, Jonathan
    Frederiksen, Klaus S.
    Lundsgaard, Dorthe
    Skak, Kresten
    Skrumsager, Birte K.
    CANCER RESEARCH, 2006, 66 (08)
  • [7] A Phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC)
    Gruenwald, Viktor
    Desar, Ingrid M. E.
    Haanen, John
    Fiedler, Walter
    Mouritzen, Ulrik
    Olsen, M. W. Braendholt
    van Herpen, Carla M. L.
    ACTA ONCOLOGICA, 2011, 50 (01) : 121 - 126
  • [8] Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial
    Schmidt, Henrik
    Brown, Janet
    Mouritzen, Ulrik
    Selby, Peter
    Fode, Kirsten
    Svane, Inge Marie
    Cook, Graham P.
    Mollerup, David Hal
    Geertsen, Poul F.
    CLINICAL CANCER RESEARCH, 2010, 16 (21) : 5312 - 5319
  • [9] Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study
    Petrella, Teresa M.
    Tozer, Richard
    Belanger, Karl
    Savage, Kerry J.
    Wong, Ralph
    Smylie, Michael
    Kamel-Reid, Suzanne
    Tron, Victor
    Chen, Bingshu E.
    Hunder, Naomi N.
    Hagerman, Linda
    Walsh, Wendy
    Eisenhauer, Elizabeth A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27) : 3396 - 3401
  • [10] Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study
    Bhatia, Shailender
    Curti, Brendan
    Ernstoff, Marc S.
    Gordon, Michael
    Heath, Elisabeth I.
    Miller, Wilson H., Jr.
    Puzanov, Igor
    Quinn, David I.
    Flaig, Thomas W.
    VanVeldhuizen, Peter
    Byrnes-Blake, Kelly
    Freeman, Jeremy A.
    Bittner, Rachel
    Hunder, Naomi
    Souza, Sonia
    Thompson, John A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2014, 2
12345